GlassScriptPhysician profile
Tessa M Janovsky
NPI 1538680079
$9,066.78
in general payments reported to CMS, 2019-2025
22 companies · $2,668 in 2025
The $2,668 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $752 · 2022: $1,033 · 2023: $1,488 · 2024: $3,126 · 2025: $2,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,927 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,350 · Consulting Fee: $940 · Travel and Lodging: $49.80 · Education: $14.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,927.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,350.00 |
| Consulting Fee | $940.00 |
| Travel and Lodging | $49.80 |
| Education | $14.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,927.75 | 2021-2025 | Livdelzi, Epclusa, Descovy |
| Madrigal Pharmaceuticals | $2,620.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $1,311.00 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.68 | 2021-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $431.25 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $234.91 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $197.89 | 2021 | |
| Intra-Sana Laboratories | $157.69 | 2022-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Astrazeneca Pharmaceuticals LP | $138.23 | 2023-2025 | |
| Lilly USA, LLC | $125.00 | 2023 | |
| Novo Nordisk INC | $79.03 | 2022 | |
| Mirum Pharmaceuticals, INC. | $52.80 | 2023-2025 | Livmarli |
| Travere Therapeutics, INC. | $44.82 | 2023 | Cholbam |
| Albireo Pharma, INC. | $38.69 | 2023 | Bylvay |
| Eisai INC. | $23.99 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eton Pharmaceuticals, INC. | $19.90 | 2025 | Galzin, Betaine Anhydrous, Nitisinone |
| Ambu INC. | $18.73 | 2022 | |
| Orphalan INC | $17.66 | 2024 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $16.37 | 2022 | |
| Exelixis INC. | $15.57 | 2022 | |
| W. L. Gore & Associates, INC. | $13.81 | 2021 | |
| Dynavax Technologies Corporation | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tessa Janovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.